Alzheimer's Disease, Cholesterol, and Statins: The Junctions of Important Metabolic Pathways

• Type: Another Publication in an International Scientific Journal
• Date: 2013

Authors

Tiago Silva (Author) Other; Jose Teixeira (Author) Other; Fernando Remiao (Author) FFUP; Fernanda Borges (Author) FCUP

Journal

Title: Angewandte Chemie - International Edition

Vol. 52

Pages: 1110-1121

ISSN: 1433-7851

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 51 Citations

Scopus - 52 Citations

Scientific classification

FOS: Natural sciences > Chemical sciences

CORDIS: Physical sciences > Chemistry > Applied chemistry > Pharmaceutical chemistry

Other information

Authenticus ID: P-002-1R6

DOI: 10.1002/anie.201204964

Abstract (EN): Recent years have seen a significant increase in published data supporting the positive effects of statins on neurodegenerative diseases, in particular on Alzheimers disease. Statins show neuroprotective activity by a combination of different cellular and systemic mechanisms that are based on the inhibition of the biosynthesis of cholesterol and isoprenoid by-products. The promising results obtained in vivo and in epidemiological studies are generally not in accordance with those of placebo-controlled randomized clinical trials. Nevertheless, these results make statins valuable assets for disease prevention rather than therapeutic agents for use when disease symptoms are already displayed. Thus, the modulation of midlife cholesterol and/or statin administration prior to the appearance of dementia or cognitive impairment may have a better long-term outcome.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 12